Holen Sie sich die Stockscreener-App
51.88
0.97%
0.50
Schlusskurs vom Vortag:
$51.38
Offen:
$51.38
24-Stunden-Volumen:
896.51K
Relative Volume:
0.58
Marktkapitalisierung:
$4.14B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-269.44M
KGV:
-13.83
EPS:
-3.75
Netto-Cashflow:
$-262.63M
1W Leistung:
+0.23%
1M Leistung:
-4.28%
6M Leistung:
+107.35%
1J Leistung:
+89.34%
1-Tages-Spanne:
$50.60
$51.98
1-Wochen-Bereich:
$50.60
$54.99
52-Wochen-Spanne:
$21.34
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Firmenname
Akero Therapeutics Inc
Sektor
Branche
Telefon
650-487-6488
Adresse
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Vergleichen Sie AKRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
51.88 | 4.13B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-30 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-01-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-11-18 | Eingeleitet | Citigroup | Buy |
| 2024-04-22 | Fortgesetzt | BofA Securities | Neutral |
| 2023-09-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-28 | Eingeleitet | UBS | Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-10-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-02-26 | Eingeleitet | Guggenheim | Buy |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-07-01 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Evercore ISI | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-15 | Eingeleitet | Jefferies | Buy |
| 2019-07-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Akero Therapeutics Inc Aktie (AKRO) Neueste Nachrichten
Readystate Asset Management LP Invests $4.07 Million in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Jennison Associates LLC Takes Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Is Akero Therapeutics Inc. a good long term investmentHigh-velocity gains - Autocar Professional
What drives Akero Therapeutics Inc. stock priceExponential wealth increase - Autocar Professional
Akero Therapeutics Inc. Stock Analysis and ForecastDynamic profit opportunities - jammulinksnews.com
Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $529,500.00 in Stock - MarketBeat
Kennondale Capital Management LLC Has $571,000 Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
What analysts say about Akero Therapeutics Inc. stockFastest-growing stock picks - jammulinksnews.com
Bank of New York Mellon Corp Purchases 12,235 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Edgestream Partners L.P. Buys Shares of 6,947 Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Xponance Inc. Buys Shares of 5,565 Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
257,025 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Purchased by Principal Financial Group Inc. - MarketBeat
Mirum Gains 35% in 3 Months: How Should You Play the Stock? - The Globe and Mail
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $82.50 Average Price Target from Analysts - MarketBeat
Emerald Advisers LLC Has $11.92 Million Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
How Akero Therapeutics Inc. stock performs during market volatilityFree Stock Market Forecasting Tools - beatles.ru
Emerald Mutual Fund Advisers Trust Sells 145,145 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng Sells 30,000 Shares - MarketBeat
Learn to Evaluate (AKRO) using the Charts - news.stocktradersdaily.com
Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $638,625.00 in Stock - MarketBeat
Akero Therapeutics CEO Cheng sells $1.5m in stock By Investing.com - Investing.com Canada
Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy Sells 2,000 Shares - MarketBeat
(AKRO) Investment Report - news.stocktradersdaily.com
Oppenheimer & Co. Inc. Invests $297,000 in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics, Inc.(NasdaqGS: AKRO) dropped from Russell 3000 Value Index - MarketScreener
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Akero Therapeutics, Inc. (NASDAQ:AKRO) CTO Scott A. Gangloff Sells 848 Shares - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $82.50 Consensus Price Target from Analysts - MarketBeat
Akero therapeutics (AKRO) SVP Lamy sells $108k in stock By Investing.com - Investing.com UK
Akero Therapeutics (NASDAQ:AKRO) Stock Price Down 3.3%Time to Sell? - MarketBeat
Don't Ignore The Insider Selling In Akero Therapeutics - simplywall.st
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 2,803 Shares of Stock - MarketBeat
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells 2,493 Shares of Stock - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $127,332.00 in Stock - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO Sells $151,387.96 in Stock - MarketBeat
Rhumbline Advisers Purchases 5,001 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Millennium Management LLC Lowers Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased By Stocktwits - Investing.com India
Akero Therapeutics (AKRO) Emerges as Attractive Acquisition Targ - GuruFocus
Finanzdaten der Akero Therapeutics Inc-Aktie (AKRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):